Pancreatic Cancer Research

ResearcherShiraz UniversityActive in the last 2 years

Omidreza Firuzi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2248-5198; OpenAlex author ID A5091349162. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
20
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 9

  1. Sertraline Has Anticancer Effects and Enhances the Cytotoxicity of Chemotherapeutic Agents Against Pancreatic Cancer Cells. Last author DOI 10.1002/ardp.70290↗
  2. Olaparib has synergistic effects with DNA damaging agents in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.bbrc.2025.153080↗
  3. Combination of chemotherapy and c-MET inhibitors has synergistic effects in c-MET overexpressing pancreatic cancer cells. Last author DOI 10.1016/j.biochi.2024.12.006↗
  4. Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence. Last author DOI 10.1016/j.bbcan.2024.189185↗
  5. Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. Last author DOI 10.1016/j.critrevonc.2022.103749↗
  6. Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases incl… Last author DOI 10.1038/s41598-021-83069-4↗
  7. Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models. Co-author DOI 10.1186/s40164-020-00176-0↗
  8. Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. Co-author DOI 10.3390/cancers11050638↗
  9. Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2017.04.006↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fatemeh Moosavi · 6 shared papers, 2021–2026 · strength 1.66
  2. Bahareh Hassani · 2 shared papers, 2024–2026 · strength 0.67
  3. Elisa Giovannetti · 4 shared papers, 2017–2022 · strength 0.49
  4. Maedeh Shahrabi · 1 shared paper, 2026 · strength 0.36
  5. Motahareh Mortazavi · 2 shared papers, 2021–2022 · strength 0.34
  6. Godefridus J. Peters · 3 shared papers, 2017–2020 · strength 0.29
  7. Pei Pei · 2 shared papers, 2019–2020 · strength 0.21
  8. Miriam Martini · 1 shared paper, 2022 · strength 0.20
  9. Tahereh Damghani · 1 shared paper, 2021 · strength 0.13
  10. Alessandro Gregori · 1 shared paper, 2020 · strength 0.13
  11. Asif Ali · 1 shared paper, 2017 · strength 0.08
  12. Adam Enver Frampton · 1 shared paper, 2017 · strength 0.08
  13. Btissame El Hassouni · 1 shared paper, 2019 · strength 0.08
  14. Ilaria Carnevale · 1 shared paper, 2019 · strength 0.08
  15. Amir Avan · 1 shared paper, 2019 · strength 0.08
  16. Thomas Schmidt · 1 shared paper, 2019 · strength 0.08
  17. Stefano Coppola · 1 shared paper, 2019 · strength 0.08
  18. Rainer Lothar Heuchel · 1 shared paper, 2019 · strength 0.08
  19. Niccola Funel · 1 shared paper, 2019 · strength 0.08
  20. Matthias J. Löhr · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.